Skip to main content
Go to homepage

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia COG AAML1331

Safety and Efficacy of Tretinoin and Arsenic Trioxide in Patients With Untreated Acute PML


For complete information, please visit the study on

Interested in participating?
We are currently recruiting
Study Sponsor:

Children's Oncology Group

Full IRB Study Title:
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid
IRB Study ID:
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program